^
Association details:
| Biomarker: | ROS1 translocation + EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan
Published date:
05/21/2022
Excerpt:
Twenty NSCLCs were detected with ROS1 translocation in 479 wild-type EGFR specimens from 2018....In these 20 ROS1 translocation cases, 19 patients received crizotinib treatment, with an objective response rate (ORR) of 78.95% (confidence interval = 69.34% to 88.56%), including 1 complete response, 14 partial responses, 3 stable cases and 1 progressive case. Overall survival and progression-free survival were better in the 19 ROS1-translocated NSCLCs of the prospective group with crizotinib treatment than the four ROS1-translocated NSCLCs of the retrospective group without crizotinib treatment....ROS1-translocated NSCLCs had a poor prognosis and could have a beneficial outcome with crizotinib.
DOI:
https://doi.org/10.3390/ijms23105789
